Your browser doesn't support javascript.
loading
Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.
Hideshima, Teru; Mazitschek, Ralph; Qi, Jun; Mimura, Naoya; Tseng, Jen-Chieh; Kung, Andrew L; Bradner, James E; Anderson, Kenneth C.
Affiliation
  • Hideshima T; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Mazitschek R; Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Qi J; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Mimura N; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Tseng JC; Department of Hematology, Chiba University Hospital, Chiba, Japan.
  • Kung AL; Lurie Family Imaging Center, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Bradner JE; PerkinElmer Inc., Hopkinton, MA, USA.
  • Anderson KC; Lurie Family Imaging Center, Dana-Farber Cancer Institute, Boston, MA, USA.
Oncotarget ; 12(17): 1736, 2021 Aug 17.
Article in En | MEDLINE | ID: mdl-34434504
[This corrects the article DOI: 10.18632/oncotarget.19019.].
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Oncotarget Year: 2021 Document type: Article Affiliation country: United States Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Oncotarget Year: 2021 Document type: Article Affiliation country: United States Country of publication: United States